Scribe Therapeutics (SCRE) investor relations material

Company overview and business model

• Clinical-stage biotech focused on in vivo CRISPR technologies for disease prevention and durable therapeutic intervention, targeting common diseases with high unmet need, especially cardiovascular and metabolic disorders.

• Lead program STX-1150 uses ELXR epigenetic silencing to lower LDL-C without permanent genetic changes; initial clinical trial underway in Australia with data expected 1H 2027.

• Pipeline includes STX-1200 (Lp(a) lowering) and STX-1400 (triglyceride lowering), both using XE gene editing, with preclinical data showing high efficacy and specificity.

• Strategic collaborations with Sanofi (rare genetic diseases) and Lilly (neurological disorders) provide capital efficiency and validate technology versatility.

• Proprietary CRISPR by Design approach leverages AI, machine learning, and parallel experimental validation to optimize technology for each application.

Financial performance and metrics

• Collaboration revenue: $51.2M in 2025, $27.4M in 2024; net losses of $21.8M in 2025 and $47.8M in 2024.

• Cash, cash equivalents, and short-term investments: $49.7M as of March 31, 2026.

• Accumulated deficit: $175.1M as of March 31, 2026.

• Operating expenses driven by R&D and G&A; company expects continued losses and will require additional capital beyond current resources.

Use of proceeds and capital allocation

• Estimated net proceeds from IPO and concurrent private placement: $96.2M (or $110.2M if underwriters exercise option in full), based on $14.00/share IPO price.

• Proceeds to fund clinical development of STX-1150 ($30–35M), advance STX-1400 and STX-1200 ($15–20M each), pipeline and technology development ($20–25M), and general corporate purposes.

• Proceeds expected to fund operations into 1H 2029; additional capital will be needed for full development and commercialization.